Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone progressive change, with variants conferring advantage rapidly becoming dominant lineages, e.g., B.1.617. With apparent increased transmissibility, variant B.1.617.2 has contributed to the current wave of infection ravaging t...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Liu, C, Ginn, HM, Dejnirattisai, W, Supasa, P, Wang, B, Tuekprakhon, A, Nutalai, R, Zhou, D, Mentzer, AJ, Zhao, Y, Duyvesteyn, HME, López-Camacho, C, Slon-Campos, J, Walter, TS, Skelly, D, Johnson, SA, Ritter, TG, Mason, C, Costa Clemens, SA, Gomes Naveca, F, Nascimento, V, Nascimento, F, Fernandes da Costa, C, Resende, PC, Pauvolid-Correa, A, Siqueira, MM, Dold, C, Temperton, N, Dong, T, Pollard, AJ, Knight, JC, Crook, D, Lambe, T, Clutterbuck, E, Bibi, S, Flaxman, A, Bittaye, M, Belij-Rammerstorfer, S, Gilbert, SC, Malik, T, Carroll, MW, Klenerman, P, Barnes, E, Dunachie, SJ, Baillie, V, Serafin, N, Ditse, Z, Da Silva, K, Paterson, NG, Williams, MA, Goulder, P, Fry, EE, Ren, J, Stuart, DI, Screaton, GR
Aineistotyyppi: Journal article
Kieli:English
Julkaistu: Elsevier 2021

Samankaltaisia teoksia